ACE OncoCast

ACE Oncology

The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.

  1. 15.11.2025

    Expert Interview of Dr Carballo: The Role of Radiotherapy for MIBC Patients

    Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. By this expert interview, you will receive a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. The course will enable clinicians who are involved in the management of patients with urothelial cancer to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care.

    5 Min.

  2. 15.11.2025

    Expert Interview of Dr Guerrero: Optimal Management for NMIBC and MIBC Patients from a Surgical Perspective

    Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. By this expert interview, you will receive a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. The course will enable clinicians who are involved in the management of patients with urothelial cancer to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care.

    17 Min.

  3. 15.11.2025

    Expert Interview of Dr Real: Molecular Pathology and Biology of Urothelial Cancer

    Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. By this expert interview, you will receive a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. The course will enable clinicians who are involved in the management of patients with urothelial cancer to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care.

    11 Min.

  4. 15.11.2025

    Expert Interview of Dr Enrique Grande: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer

    Enrique Grande, MD, MSc, PhD  Quirónsalud Madrid Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies.   By this expert interview, you will receive a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. The course will enable clinicians who are involved in the management of patients with urothelial cancer to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care.

    20 Min.

  5. 07.11.2024

    Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (1 of 2)

    Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship’, in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download. Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.

    13 Min.

  6. 07.11.2024

    Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (2 of 2)

    Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship’, in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download. Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.

    4 Min.

  7. 05.11.2024

    Expert Interview of Specialist Insights in Urothelial Cancer: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer

    Enrique Grande, MD, MSc, PhD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship’, in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download. Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.

    25 Min.

  8. 05.11.2024

    Expert Interview of Specialist Insights in Urothelial Cancer: Molecular Pathology and Biology of Urothelial Cancer

    Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship’, in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download. Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.

    15 Min.
Alle anzeigen (50)

Info

The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.

Informationen

  • Erstellt von
    ACE Oncology
  • Jahre aktiv
    2022 - 2025
  • Folgen
    50
  • Bewertung
    Unbedenklich
  • Copyright
    © 2026 ACE OncoCast
  • Sendungswebsite
    ACE OncoCast